What Is 21 CFR Part 11 Compliance?
21 CFR Part 11 compliance refers to meeting the U.S. Food and Drug Administration requirements for electronic records and electronic signatures used in regulated environments. For life sciences companies, this regulation defines how systems, processes, and controls must work so electronic records are trustworthy, reliable, and equivalent to paper records.
The goal of 21 CFR Part 11 compliance is not just technical control. It is operational accountability. Organizations must be able to show who accessed a record, what changed, when it changed, why it changed, and whether the system can prevent unauthorized activity. In practice, that means compliant environments need validated systems, secure access controls, robust audit trails, and traceable eSignature processes.
At a minimum, companies should be able to answer questions like these:
- Is access restricted to authorized individuals only?
- Are authority checks in place so only approved users can sign, edit, or review records?
- Are electronic signatures permanently linked to the record and captured with the signer’s name, date, time, and meaning?
- Do audit trails track changes in a way that cannot be obscured or overwritten?
- Can the system identify and report unauthorized access attempts?
- For background on the regulation itself, see the FDA’s Part 11 guidance.
It is also important to understand the scope of Part 11. The regulation only applies to electronic records that are required to be created or maintained under a predicate rule, such as Good Manufacturing Practice (GMP), Good Clinical Practice (GCP), or Good Laboratory Practice (GLP). FDA’s 2003 Scope and Application guidance further established a risk-based, narrow interpretation, meaning that organizations should apply Part 11 controls in proportion to the record’s impact on product quality, patient safety, and data integrity. Part 11 also distinguishes between closed systems (where access is controlled by the entity responsible for the records) and open systems (where access is not controlled by that entity), with additional requirements for open systems. Hybrid environments, which combine paper and electronic records, are still common in life sciences and require clear procedures to ensure the full record set remains complete, attributable, and traceable.
Why 21 CFR Part 11 Compliance Matters in Life Sciences
For regulated companies, 21 CFR Part 11 compliance is closely tied to product quality, patient safety, inspection readiness, and business continuity. Electronic systems are now central to quality, manufacturing, clinical, and regulatory operations. If those systems are not compliant, the risk is not limited to documentation gaps. It can affect data integrity, submission readiness, audit outcomes, and confidence in the business process itself.
Strong compliance programs support:
- Secure and traceable electronic records
- Reliable electronic signatures
- Better inspection and audit readiness
- Lower risk of data integrity issues
- More efficient digital workflows across regulated functions
This is why Trust & Compliance (USDM’s service line for quality, validation, and regulatory compliance) has to be built into the operating model, not bolted on after deployment.
Core Requirements for 21 CFR Part 11 Compliance
A strong 21 CFR Part 11 compliance program typically includes several foundational controls.
Audit Trails: Audit trails must capture critical user and system activity related to regulated records. That includes record creation, modification, review, approval, and deletion where applicable. A compliant audit trail should preserve timestamps, user identity, and change history in a way that supports inspection and investigation.
Event logs alone are not enough. The system needs granular, reviewable traceability.
Access Controls: Access must be limited to authorized individuals based on role and responsibility. That includes unique user IDs, authentication controls, and permission structures that prevent unauthorized viewing, editing, or signing of records.
Electronic Signatures: Electronic signatures must be attributable to one individual and linked to the signed record. Systems should capture signature meaning, such as approval, review, or authorship, along with the signer’s identity and timestamp.
Several specific provisions drive how eSignatures are implemented in practice. Section 11.50 requires that signed electronic records display the printed name of the signer, the date and time of signing, and the meaning of the signature. Section 11.70 requires that the signature be linked to the record so it cannot be excised, copied, or otherwise transferred to falsify another record. For non-biometric signatures, Section 11.100 and 11.200 require that each signature use at least two distinct identification components, such as an ID and a password, and that the organization submit a certification letter to FDA stating that its electronic signatures are intended to be the legally binding equivalent of handwritten signatures. These are the controls that inspectors most often probe.
System Validation: A compliant system must consistently perform as intended. Validation demonstrates that the technology, configuration, and supporting procedures work together to protect regulated records and signatures. FDA’s 2022 Computer Software Assurance (CSA) guidance for production and quality system software builds on traditional Computer System Validation (CSV) by encouraging a risk-based approach that emphasizes critical thinking, unscripted testing, and assurance activities proportionate to a system’s impact on product quality and patient safety. For many GxP systems, a CSA approach reduces validation burden while strengthening the focus on the controls that matter most to Part 11 compliance.
Security and Monitoring: Organizations need mechanisms to detect unauthorized access attempts, monitor critical activity, and respond appropriately to risk. Continuous oversight helps maintain compliance as systems, users, and integrations evolve.
Building 21 CFR Part 11 Compliance Into Audit-Ready Processes
The most effective approach to 21 CFR Part 11 compliance combines technology, governance, and day-to-day operating discipline. Compliance is stronger when processes are designed to be audit-ready from the start.
Key compliance measures include:
- Documented validation and change control
- Role-based access and authority checks
- Reviewable, secure audit trails
- Controlled eSignature workflows
- Ongoing monitoring of system state and risk
USDM helps life sciences companies operationalize these controls through services such as Cloud Assurance™, which supports continuous compliance validation, risk reduction, and audit readiness across regulated platforms.
Using Workflow Automation to Strengthen 21 CFR Part 11 Compliance
Manual compliance processes create friction, increase review burden, and leave room for inconsistency. Intelligent automation improves both efficiency and control when it is designed for regulated use.
With Intelligent Workflow Automation (USDM’s service line for process automation and orchestration across regulated business functions), organizations can embed compliance checkpoints directly into business processes. That means approvals, escalations, routing, documentation, and review actions happen in a structured and traceable way.
Benefits of automation include:
- Reduced manual effort in validation and review workflows
- More consistent execution of regulated processes
- Clearer traceability across approvals and handoffs
- Faster completion of repetitive compliance tasks
- Better integration with quality and content systems
Used well, automation supports 21 CFR Part 11 compliance by making the compliant path the default path.
Data Integrity and 21 CFR Part 11 Compliance
Data integrity sits at the center of 21 CFR Part 11 compliance. If records are incomplete, inconsistent, or difficult to trace, the compliance posture weakens quickly.
That is why regulated companies need strong data governance, connected systems, and visibility into how records move across the organization. USDM’s Data Insight and Control (USDM’s service line for data governance, analytics, and integrity across regulated platforms) capability helps organizations improve oversight while preserving security and traceability.
Important elements include:
- Data integrity controls that protect accuracy and reliability
- Governance frameworks for secure handling and retention of regulated data
- Integration across platforms so records remain connected and reviewable
- Real-time insight to support smarter, faster compliance decisions
When data is unified and governed well, compliance becomes easier to sustain.
Document Management and Content Control
Document management is another critical part of 21 CFR Part 11 compliance. Regulated content must be controlled across creation, review, approval, revision, retrieval, and archival.
USDM’s Content Management (USDM’s service line for regulated document and content lifecycle management) capability helps life sciences organizations manage unstructured content in a compliant, scalable way.
Important document control capabilities include:
- eSignature workflows with compliant controls for platforms such as DocuSign and Adobe Sign
- Version control to preserve full revision history
- Metadata management for faster retrieval and stronger searchability
- Lifecycle governance that supports inspection readiness
These capabilities help ensure regulated content remains usable, traceable, and defensible.
21 CFR Part 11 Compliance in Cloud Environments
Cloud adoption does not reduce regulatory responsibility. It changes how companies must manage it. As life sciences organizations modernize their systems, they need cloud strategies that support validation, security, and ongoing control.
USDM helps clients build compliant cloud environments through:
- End-to-end cloud compliance services
- Continuous validation approaches
- Fit-for-purpose vendor selection
- Operational controls that support evolving platforms
Whether the need is secure eSignatures, compliant content workflows, or validated cloud applications, the goal stays the same: maintain 21 CFR Part 11 compliance without slowing the business down.
21 CFR Part 11 Compliance for AI and GxP AI Systems
As life sciences organizations adopt AI and generative AI in GxP-regulated processes, 21 CFR Part 11 still applies wherever the AI system creates, modifies, or signs an electronic record required by a predicate rule. What changes is the nature of the controls. AI systems introduce non-deterministic behavior, model and prompt versioning, and shared accountability between the model, the user, and the organization. Each of these has direct implications for Part 11.
Audit Trails for Non-Deterministic Outputs: Traditional Part 11 audit trails assume that the same input produces the same output. Large language models and other AI systems do not. To preserve traceability, audit trails for AI-influenced records should capture more than the final value. At a minimum, they should record the model identifier and version, the prompt or input provided to the model, any retrieval context or grounding sources, the raw model output, the human reviewer’s action (accept, edit, reject), and the final committed record. Together, these elements allow inspectors to reconstruct how the record came to be, even when the model itself cannot be re-run deterministically.
Attribution When AI Is in the Loop: Part 11 requires that records be attributable to a specific individual. AI systems are not legal persons and cannot themselves be the attributable signer of a regulated record. Where AI generates content, drafts a decision, or proposes a value, the audit trail should clearly distinguish the AI-generated component from the human contribution, and the accountable individual must remain a named person operating under defined authority. This is consistent with FDA’s 2025 draft guidance on AI used to support regulatory decision-making and with the credibility assessment framework it describes.
Human-in-the-Loop Signature Accountability: Human-in-the-Loop (HITL) is the most defensible pattern for applying eSignatures to AI-influenced records in GxP. A qualified individual must meaningfully review the AI output before signing, the system must present enough context for that review to be substantive rather than rubber-stamp, and the signature must continue to capture the signer’s name, date, time, and meaning under Sections 11.50 and 11.70. The level of human oversight should scale with the risk of the use case: higher-risk decisions (release, batch disposition, clinical safety) demand stronger HITL controls than low-risk drafting or summarization tasks.
Validation of AI features should extend Part 11 controls in proportion to risk, covering model selection rationale, intended use, change control over prompts and model versions, ongoing performance monitoring, and the boundaries of acceptable AI behavior. A risk-based, CSA-aligned approach allows organizations to adopt AI in regulated workflows without compromising the integrity of the records the regulation is designed to protect.
How USDM Helps Life Sciences Companies Achieve 21 CFR Part 11 Compliance
USDM brings together regulatory expertise, modern technology, and practical implementation experience to help life sciences organizations simplify and strengthen compliance programs.
Our approach combines:
- Trust & Compliance
- Intelligent Workflow Automation
- Data Insight and Control
- Content Management
- Access to the best of technology
That combination helps organizations build compliant systems that are also scalable, efficient, and ready for what comes next.
Additional Resources
- Case study: DocuSign in 7 Days to Enable eSignatures for Remote Work
- Case study: Biotech Completes 70% of eSignatures Within 24 Hours
- Case study: AI Chatbots to Support GxP Content for Clinical Trials
Ready to Improve Your 21 CFR Part 11 Compliance Program?
If you are evaluating systems, modernizing processes, or trying to reduce compliance risk in regulated operations, contact us. USDM can help you build a practical, audit-ready approach to 21 CFR Part 11 compliance.